Conferences - Results from #8380

EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC) April 23, 2014

EAU 2014 - Poster: Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials April 16, 2014

EAU 2014 - Poster: Greater short-term relief of lower urinary tract symptoms in prostate cancer patients treated with degarelix compared to goserelin plus bicalutamide: Results of a pooled analysis April 16, 2014

EAU 2014 - Poster: Consistent long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: Final results of repeated treatments up to 4 years April 16, 2014

EAU 2014 - Poster: OnabotulinumtoxinA reduces urinary incontinence and improves quality of life in overactive bladder patients regardless of use of clean intermittent catheterisation or the presence of urinary tract infection April 16, 2014

EAU 2014 - Poster: An economic model to investigate differences in resource utilisation associated with the use of BOTOX® to manage urinary incontinence in patients with idiopathic overactive bladder in the United Kingdom April 16, 2014

EAU 2014 - Poster: Consistent improvements in urinary urgency following repeat onabotulinumtoxinA treatments in patients with overactive bladder syndrome and urinary incontinence April 16, 2014

EAU 2014 - Poster: Cost-utility analysis of onabotulinumtoxinA vs best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy April 16, 2014

EAU 2014 - Poster: Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial April 16, 2014

EAU 2014 - Poster: Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase and prostate-specific antigen in patients with castration-resistant prostate cancer and symptomatic bone metastases from the phase 3 ALSYMPCA trial April 16, 2014

EAU 2014 - Poster: A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses April 15, 2014

EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials April 15, 2014

EAU 2014 - Poster: Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 April 15, 2014

EAU 2014 - Nephron sparing surgery does not decrease other-causes mortality relative to radical nephrectomy in patients with clinical T1a-T1b renal mass: Results from a large multi-institutional study - Session Highlights April 15, 2014

EAU 2014 - A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses - Session Highlights April 15, 2014

EAU 2014 - Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation - Session Highlights April 15, 2014

EAU 2014 - Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial - Session Highlights April 15, 2014

EAU 2014 - Long-term immunotherapy by dendritic-cells based vaccine in patients with PSA-recurrent prostate cancer - Session Highlights April 15, 2014

EAU 2014 - Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid - Session Highlights April 15, 2014

EAU 2014 - Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials - Session Highlights April 15, 2014

Page 420 of 472

email news signup